Rutgers State University of New Jersey

真正有价值的科学创新，总是植根于对生命与环境的尊重。作为CRDMO赋能平台，药明康德不仅致力于帮助全球合作伙伴加速新药研发、守护全球病患的健康，也作为负责的企业公民不断为社会和环境带来积极的影响。▲药明康德新泽西基地员工在博物馆做“绿色志愿者”新泽西州位于美国东北走廊中心地带，是生物医药行业最具活力的创新中心之一。这里集聚了罗格斯大学、普林斯顿大学等一流学术资源，以及大量药企和3000多家生命科学机构，吸引了超过20万的科学家和工程师人才，为产业蓬勃发展提供坚实支撑。据统计，全球前20大医药公司中，有13家在当地设立了区域性总部，也让新泽西州获得了“全美药箱”的美誉。▲药明康德在美国新泽西州克兰伯里（上）和平原市（下）的实验室作为药明康德全球网络的重要组成部分，新泽西基地坐落于新泽西州中部，主要为全球合作伙伴提供全面的生物分析（BAS）和药代动力学（DMPK）服务，满足从药物发现、临床前IND申报到临床研究的新药研发全生命周期的多元化测试需求。该基地与其他团队紧密协同，共同助力全球创新。“药明康德是非常出色的合作伙伴。我特别想强调药明康德在美国的新泽西基地，他们真正让我们能进行一些特定的生物分析工作。此外，药明康德团队快速响应，为我们的项目提供高水平的支持。”致力于围绕mTOR信号通路开发新药的美国生物技术公司Navitor Pharmaceuticals高管曾表示，与药明康德的合作令人印象深刻。从新泽西的实验室，到世界的许多角落，都有着药明康德对科学的承诺、对产业的贡献、对社区内的回馈。多年来，药明康德的全球运营体系遍布欧、美、亚，各个基地紧密协同，以“一体化，端到端”CRDMO赋能平台的灵活性和规模，支持全球合作伙伴不断增长的创新需求，为患者带来好药新药，并将绿色理念融入全球运营的每一个环节。在刚刚过去的周末，药明康德在美国和欧洲多个基地的员工连同亲友参加了当地社区的世界地球日活动。其中，新泽西基地团队来到普林斯顿市中心的莫文博物馆（Morven Museum and Garden），作为“绿色志愿者”向数百名博物馆游客讲述环保的意义。这是药明康德将绿色发展融入日常的缩影，也是我们深植每一块创新热土、与生态圈共生共长的写照。地球日只是一天，我们的承诺贯穿始终。作为全球健康产业的贡献者，药明康德将继续通过负责任的运营，以及一体化赋能平台的能力与技术，赋能医药创新，共建人类与环境可持续发展的美好未来。As a leading global CRDMO enabling platform, WuXi AppTec is dedicated not only to accelerating new drug discovery and safeguarding patient health worldwide, but also to making a positive impact on society and the environment as a responsible corporate citizen. This past weekend, employees and their families from several WuXi AppTec sites across the United States and Europe participated in local community activities to celebrate Earth Day. Among them, our New Jersey team volunteered at the Morven Museum and Garden in downtown Princeton, where they served as "green ambassadors" to promote environmental awareness. This reflects how WuXi AppTec integrates sustainability into everyday operations and thrives in harmony with the innovation ecosystems we call home. New Jersey, located at the heart of the U.S. Northeast Corridor, is one of the most vibrant innovation centers for the biopharmaceutical industry. It is home to premier academic institutions such as Rutgers University and Princeton University, more than 10 multinational pharmaceutical giants, and over 3,000 life sciences organizations, attracting a talent pool of more than 200,000 scientists and engineers to support the industry's rapid growth. 13 of the world’s top 20 pharmaceutical companies have established regional headquarters in New Jersey, earning the state its reputation as "America’s Medicine Chest."As an important part of WuXi AppTec’s global network, our New Jersey site is located in Central New Jersey and provides comprehensive Bioanalytical Services (BAS) and Drug Metabolism and Pharmacokinetics (DMPK) services. These offerings support the entire lifecycle of drug discovery and development, from IND-enabling studies to clinical trials, meeting diverse testing needs through close collaboration with other global teams."WuXi AppTec has been an outstanding partner. I particularly want to highlight the New Jersey team, who have enabled us to perform specific bioanalytical work at a high level. Their responsiveness and technical support have been critical to the success of our projects," shared a senior executive from Navitor Pharmaceuticals, a U.S. biotech company developing therapies targeting the mTOR signaling pathway.From our laboratories in New Jersey to communities around the world, WuXi AppTec's commitment to science, innovation, and community impact remains steadfast. Through the flexibility and scale of our integrated, end-to-end CRDMO platform, our global operations across Europe, the Americas, and Asia are closely coordinated to support the growing innovation needs of partners worldwide—bringing better medicines to patients and embedding sustainability into every facet of our operations.While Earth Day lasts only one day, our commitment is ongoing. As a contributor to the global health ecosystem, WuXi AppTec will continue to drive responsible operations and empower pharmaceutical innovation—helping build a sustainable future for both humanity and the planet.免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Ted Schroeder to its Board of Directors. Mr. Schroeder brings more than three decades of experience leading innovative biopharmaceutical companies and has a strong track record of building and scaling commercial organizations, bringing new therapies to market, and successfully guiding companies through key business milestones and strategic transactions. “We are pleased to welcome Ted to the Phathom Board during a pivotal period for the company,” said Michael Cola, Chairman of the Board, Phathom Pharmaceuticals. “Ted is a seasoned biopharma leader with a strong history of developing and commercializing innovative treatments, scaling growth-focused organizations, and creating shareholder value. As Phathom continues to unlock the full potential of VOQUEZNA®, Ted’s deep operational and commercial expertise will be an important asset. We look forward to his insights and partnership as we work to accelerate our commercial momentum and deliver our first-in-class therapies to patients in need.” About Ted SchroederMr. Schroeder served as Chief Executive Officer of Nabriva Therapeutics from 2018 to 2023 and as a director until March 2025, following Nabriva’s acquisition of Zavante Therapeutics, where he was co-founder, President, and CEO. Prior to that, he co-founded Cadence Pharmaceuticals and served as President and CEO until its $1.4 billion acquisition by Mallinckrodt Pharmaceuticals in 2014. Earlier in his career, he held senior leadership roles at Elan Pharmaceuticals, Dura Pharmaceuticals, and Bristol-Myers Squibb. Mr. Schroeder currently serves on the Board of Directors of Cidara Therapeutics (Nasdaq: CDTX) and has previously served on the boards of several public and private life sciences companies, including Otonomy, Collegium Pharmaceutical, Hyperion Therapeutics, Incline Therapeutics, and Trius Therapeutics. He is also a former Chairman of Biocom California and the Antimicrobials Working Group. In 2014, he was named EY Entrepreneur of the Year for the San Diego region and was recognized as a national finalist. He holds a B.S. in Management from Rutgers University. About Phathom Pharmaceuticals, Inc.Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com follow on LinkedIn and X. MEDIA CONTACTNick Benedetto1-877-742-8466media@phathompharma.com INVESTOR CONTACTEric Sciorilli1-877-742-8466ir@phathompharma.com © 2025 Phathom Pharmaceuticals. All rights reserved.VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.

2025年3月27日，Nature发表文章AlphaFold is running out of data — so drug firms are building their own version，主要描述了面对AlphaFold在蛋白质与药物相互作用数据上的不足，多家制药公司合作利用内部专有数据开发不向学术界开放的私有AI模型，以提升药物研发能力。AlphaFold这一革命性的诺贝尔奖获奖蛋白质结构预测工具正面临一个问题：数据即将耗尽。David Baker、Demis Hassabis和John Jumper（从左到右）因开发出可以预测和设计蛋白质结构的计算工具而获得诺贝尔化学奖。最新版本的人工智能模型AlphaFold 3被誉为药物研发领域的颠覆者，因为它能模拟蛋白质与其他分子（包括药物）的相互作用。但科学家指出，由于AlphaFold的基础数据（数十万公开的蛋白质结构）中缺乏这些相互作用的实例，该工具在制药公司最关注的应用领域仍受限制。近日，由多家领先制药公司组成的联盟宣布计划利用其内部数据库中数千个目前保密的蛋白质结构，开发一款受AlphaFold 3启发的AI模型。这些数据将补充蛋白质数据库（Protein Data Bank, PDB）中已有的20多万个公开蛋白质结构。“PDB中缺失的数据正是我们内部数据所包含的部分”，艾伯维计算药物发现负责人、参与该项目的John Karanicolas表示。该联盟名为“AI结构生物学联盟(AI Structural Biology Consortium)”。AISB联盟是一项旨在帮助改变药物发现和开发的新型合作来源：https://www.apheris.com/industries/aisb该联盟的模型基于OpenFold 3，将于4月发布。但该模型仅限成员公司（包括艾伯维、强生、赛诺菲和勃林格殷格翰）使用，暂无向外界开放的计划。开发AlphaFold的DeepMind未参与此项目且拒绝置评。其子公司Isomorphic Labs正将AlphaFold 3用于与诺华和礼来等药企的合作中。药物数据短缺AlphaFold通过蛋白质序列预测其3D结构的能力依赖于PDB中通过X射线晶体学等实验方法获得的海量蛋白质结构数据。Karanicolas指出，这些结构数据中虽包含相互作用分子，但多为ATP（细胞能量来源）等生物分子，而非药物化合物。哥伦比亚大学计算生物学家、OpenFold开发负责人Mohammed AlQuraishi表示，AlphaFold 3在预测蛋白质与潜在药物相互作用方面表现尚可，但“这仍是一个开放性问题”。药企内部极少公开的蛋白质结构可能为此提供帮助。在药物开发过程中，企业通常会针对同一蛋白质与多种候选药物结合的结构进行测定。罗格斯大学结构生物学家Stephen K. Burley称，这些专有蛋白质结构数据的完整规模尚不明确，但其总量可能与PDB相当甚至更大。仅艾伯维一家公司就为联盟的AI模型贡献了超过9,000个结构。AlQuraishi感叹道：“这些封闭数据库中的数据量令人震惊。”为开发新模型，制药公司不会彼此共享实际蛋白质结构数据，也不会与AlQuraishi分享。取而代之的是，他们将使用柏林初创公司Apheris开发的平台，在数据不离开企业数字防火墙的前提下，利用专有数据对OpenFold 3进行再训练。Karanicolas强调，该模型无法通过逆向工程识别其训练所用的保密结构。AlQuraishi表示，额外数据能否提升AlphaFold对蛋白质-药物相互作用的建模能力仍不明确。“关键问题在于提升幅度有多大？”他的团队将通过对比模型预测与实验结果来评估性能，并公开详细分析。“无论结果积极或消极，这项实验都极具价值”，他补充道。AlQuraishi指出，一些科学家和资助机构正计划建立类似药企的结构数据库以训练AI模型，而验证更多数据是否真正有用将至关重要。显著提升田纳西州纳什维尔范德堡大学计算结构生物学家Stephanie Wankowicz表示：“仅凭制药公司的保密数据可能无法提升AlphaFold在蛋白质预测方面本已卓越的准确性。企业数据中蕴含的化学多样性或能“极大改善”药物相互作用的预测。”加州大学旧金山分校药物化学家Brian Shoichet则质疑药企是否拥有足够数据推动AlphaFold实现重大突破。“他们能从这颗‘柠檬’中榨取的创新终究有限”，他说道。然而，Shoichet指出，即使小幅改进也可能极具价值，例如更精准预测药物是否会与特定蛋白质结合——这能间接反映药物有效性。他的团队正在进行“虚拟对接”实验：通过基于物理原理的软件，从数十亿化合物中筛选可能与目标蛋白质结合的候选分子，再通过实验室测试验证预测结果。“若20%的预测有效，我们已感欣慰。若能提升至50%，将是质的飞跃。”他解释道。数据开放的争议与希望目前，联盟模型仅限成员使用，Karanicolas希望更多药企加入。他称，联盟计划先评估模型表现，再考虑向学术界开放。Wankowicz更希望药企能从根本上公开更多结构数据。Burley指出，在PDB的23.3万个结构中，仅6%由制药公司提交。Shoichet虽认同药企有充分理由应共享更多结构数据，但对实际进展不抱期待。“这类讨论我参与了30年，却从未实现过。如今我已不再提及此事。”Burley则更乐观，他认为企业终将认识到开放带来的益处（如更强大的药物研发工具）。“在后AlphaFold 2和AlphaFold 3时代，企业会更愿意迈出这信念的飞跃。”参考资料：https://doi-org.libproxy1.nus.edu.sg/10.1038/d41586-025-00868-9--------- End ---------感兴趣的读者，可以添加小邦微信加入读者实名讨论微信群。添加时请主动注明姓名-企业-职位/岗位或姓名-学校-职务/研究方向。